Buccioni Michela

Dr. Buccioni Michela

University of Camerino, School of Pharmacy, Medicinal Chemistry Unit
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2016 in Food & Function
Verified
Journal Article
Closed access
PDF file
Giovanni CaprioliGiovanni Caprioli
Giovanni Caprioli
RIRomilde Iannarelli
Romilde Iannarelli
MIMarzia Innocenti
Marzia Innocenti
MBMaria Bellumori
Maria Bellumori
DFDennis Fiorini
Dennis Fiorini
Filippo MaggiFilippo Maggi
Filippo Maggi
In the present work we conducted a comprehensive chemical analysis of blue honeysuckle (Lonicera caerulea) spontaneously growing in eastern Russia. HPLC-DAD-ESI/MS analysis showed cyanidin-3-glucoside as the major constituent among phenolics, while nutritional analysis revealed fibre, protein, calcium and magnesium as the most important macro- and micronutrients, respectively. Fatty acid composition was dominated by polyunsaturated fatty acids, linoleic acid being the most abundant. Furthermore, we evaluated several in vitro biological activities such as antioxidant, antimicrobial, antiproliferative, wound healing and immunomodulatory effects of blue honeysuckle aqueous and ethanolic extracts that are often incorporated in food and nutraceutical preparations. While the fruit extracts were revealed to be potent radical scavengers with significant inhibition of ABTS radical, thus confirming the literature data, their inhibitory effects against microbial pathogens and tumor cell lines were negligible. The fruit aqueous extract did not show toxicity to human fibroblasts, but 24 h treatment with 150–200 μg per mL of extract slightly enhanced the cell migration when tested by scratched wound assay. Worth mentioning was the inhibitory effect displayed by the blue honeysuckle fruit aqueous extract on human lymphocytes.

21 July 2020 in Cells
Verified
Journal Article
Open access
PDF file
ANAleix Marti Navi
Aleix Marti Navi
Diego Dal BenDiego Dal Ben
Diego Dal Ben
Catia LambertucciCatia Lambertucci
Catia Lambertucci
ASAndrea Spinaci
Andrea Spinaci
Rosaria VolpiniRosaria Volpini
Rosaria Volpini
BMBuccioni Michela
Buccioni Michela
The pathological condition of neuroinflammation is caused by the activation of the neuroimmune cells astrocytes and microglia. The autacoid adenosine seems to be an important neuromodulator in this condition. Its main receptors involved in the neuroinflammation modulation are A1AR and A2AAR. Evidence suggests that A1AR activation produces a neuroprotective effect and A2AARs block prevents neuroinflammation. The aim of this work is to elucidate the effects of these receptors in neuroinflammation using the partial agonist 2′-dCCPA (2-chloro-N6-cyclopentyl-2′-deoxyadenosine) (C1 KiA1AR = 550 nM, KiA2AAR = 24,800 nM, and KiA3AR = 5560 nM, α = 0.70, EC50A1AR = 832 nM) and the newly synthesized in house compound 8-chloro-9-ethyl-2-phenethoxyadenine (C2 KiA2AAR = 0.75 nM; KiA1AR = 17 nM and KiA3AR = 227 nM, IC50A2AAR = 251 nM unpublished results). The experiments were performed in in vitro and in in vivo models of neuroinflammation. Results showed that C1 was able to prevent the inflammatory effect induced by cytokine cocktail (TNF-α, IL-1β, and IFN-γ) while C2 possess both anti-inflammatory and antioxidant properties, counteracting both neuroinflammation in mixed glial cells and in an animal model of neuroinflammation. In conclusion, C2 is a potential candidate for neuroinflammation therapy.

14 November 2016 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
GMGabriella Marucci
Gabriella Marucci
Diego Dal BenDiego Dal Ben
Diego Dal Ben
CLCatia Lambertucci
Catia Lambertucci
CSClaudia Santinelli
Claudia Santinelli
ASAndrea Spinaci
Andrea Spinaci
BMBuccioni Michela
Buccioni Michela

26 July 2024 in Molecules
Verified
Journal Article
Open access
PDF file
Katharigatta VenugopalaKatharigatta Venugopala
Katharigatta Venugopala
BMBuccioni Michela
Buccioni Michela
Cancer, a complex array of diseases, involves the unbridled proliferation and dissemination of aberrant cells in the body, forming tumors that can infiltrate neighboring tissues and metastasize to distant sites. With over 200 types, each cancer has unique attributes, risks, and treatment avenues. Therapeutic options encompass surgery, chemotherapy, radiation therapy, hormone therapy, immunotherapy, targeted therapy, or a blend of these methods. Yet, these treatments face challenges like late-stage diagnoses, tumor diversity, severe side effects, drug resistance, targeted drug delivery hurdles, and cost barriers. Despite these hurdles, advancements in cancer research, encompassing biology, genetics, and treatment, have enhanced early detection methods, treatment options, and survival rates. Adenosine receptors (ARs), including A1, A2A, A2B, and A3 subtypes, exhibit diverse roles in cancer progression, sometimes promoting or inhibiting tumor growth depending on the receptor subtype, cancer type, and tumor microenvironment. Research on AR ligands has revealed promising anticancer effects in lab studies and animal models, hinting at their potential as cancer therapeutics. Understanding the intricate signaling pathways and interactions of adenosine receptors in cancer is pivotal for crafting targeted therapies that optimize benefits while mitigating drawbacks. This review delves into each adenosine receptor subtype’s distinct roles and signaling pathways in cancer, shedding light on their potential as targets for improving cancer treatment outcomes.

1 November 2020 in Pharmacological Research
Verified
Journal Article
Closed access
JWJunbiao Wang
Junbiao Wang
RIRomilde Iannarelli
Romilde Iannarelli
SPStefania Pucciarelli
Stefania Pucciarelli
Emiliano LaudadioEmiliano Laudadio
Emiliano Laudadio
Roberta GaleazziRoberta Galeazzi
Roberta Galeazzi
AAAugusto Amici
Augusto Amici

1 January 2014 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
BMBuccioni Michela
Buccioni Michela
Diego Dal BenDiego Dal Ben
Diego Dal Ben
CLCatia Lambertucci
Catia Lambertucci
Filippo MaggiFilippo Maggi
Filippo Maggi
FPFabrizio Papa
Fabrizio Papa
GMGabriella Marucci
Gabriella Marucci
The anticancer activity of isofuranodiene, extracted fromSmyrnium olusatrum, was evaluated in human breast adenocarcinomas MDA-MB 231 and BT 474, and Caucasian prostate adenocarcinoma PC 3 cell lines by MTS assay. MTS assay showed a dose-dependent growth inhibition in the tumor cell lines after isofuranodiene treatment. The best antiproliferative activity of the isofuranodiene was found on PC 3 cells with an IC50value of 29 μM, which was slightly less than the inhibition against the two breast adenocarcinoma cell lines with IC50values of 59 and 55 μM on MDA-MB 231 and BT 474, respectively. Hoechst 33258 assay was performed in order to study the growth inhibition mechanism in prostate cancer cell line; the results indicate that isofuranodiene induces apoptosis. Overall, the understudy compound has a good anticancer activity especially towards the PC 3. On the contrary, it is less active on Chinese hamster ovary cells (CHO) and human embryonic kidney (HEK 293) appearing as a good candidate as a potential natural anticancer drug with low side effects.